Publicacions en col·laboració amb investigadors/es de Hospital Clinic Barcelona (21)

2024

  1. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

  2. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

2023

  1. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

2021

  1. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  2. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

    Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456

  3. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

    Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936

2018

  1. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: The EPIPHANY study

    European Respiratory Journal, Vol. 49, Núm. 1

  2. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

    Tumor Biology, Vol. 39, Núm. 6

  3. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: Real-world data from the AGAMENON National Cancer Registry

    British Journal of Cancer, Vol. 117, Núm. 6, pp. 775-782

  4. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

    Gastric Cancer, Vol. 20, Núm. 3, pp. 465-474

  5. Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients

    Journal of the National Cancer Institute, Vol. 109, Núm. 4

  6. Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study

    European Journal of Radiology, Vol. 87, pp. 66-75

2016

  1. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

    British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198

  2. On the effect of triplet or doublet chemotherapy in advanced gastric cancer: Results from a national cancer registry

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 11, pp. 1379-1388

  3. Outpatient management of cancer-associated pulmonary embolism (PE): analysis of lung carcinoma (LC) cohort from the Epiphany study

    Annals of Oncology, Vol. 27, pp. vi513

2015

  1. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

    PLoS ONE, Vol. 10, Núm. 1

  2. Embolia pulmonar en el paciente oncológico: bases para el estudio EPIPHANY

    Medicina Clinica, Vol. 144, Núm. S1, pp. 31-37

2014

  1. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

    British Journal of Cancer, Vol. 111, Núm. 2, pp. 241-248